All In Biotech

NDA 205636 · Teva Branded Pharm

Proair Respiclick

Albuterol Sulfate · Inhalation

Last checked: Nov 20, 2026Latest source record: Aug 28, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2015

Mar 31, 2015

Approved uses

2

Original approval plus efficacy supplements

Registered trials

793

238 Phase 3, 24 recruiting

FAERS reports

93,526

37,173 serious, 4,121 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jun 30, 2022.

ProAir Digihaler is a beta 2 -adrenergic agonist indicated for: Treatment or prevention of bronchospasm in patients 4 years of age and older with reversible obstructive airway disease. ( 1.1 ) Prevention of exercise-induced bronchospasm in patients 4 years of age and older. ( 1.2 ) 1.1 Bronchospasm ProAir ® Digihaler ® is indicated for the treatment or prevention of bronchospasm in patients 4 years of age and older with reversible obstructive airway disease. 1.2 Exercise-Induced Bronchospasm ProAir Digihaler is indicated for the prevention of exercise-induced bronchospasm in patients 4 years of age and older. 1.2 Exercise-Induced Bronchospasm ProAir Digihaler is indicated for the prevention of exercise-induced bronchospasm in patients 4 years of age and older.

Mechanism: Albuterol sulfate is a beta 2 -adrenergic agonist. The pharmacologic effects of albuterol sulfate are attributable to activation of beta 2 -adrenergic receptors on airway smooth muscle. Activation of beta 2 -adrenergic receptors leads to the activation of adenylcyclase and to an increase in the intracellular concentration of cyclic-3',5’‑adenosine monophosphate (cyclic AMP). This increase of cyclic AMP is associated with the activation of protein kinase A, which in turn inhibits the phosphorylation of myosin and lowers intracellular ionic calcium concentrations, resulting in muscle...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • PROAIR RESPICLICK · ALBUTEROL SULFATE EQ 0.09MG BASE/INH · POWDER, METERED, INHALATION · Prescription
  • PROAIR DIGIHALER · ALBUTEROL SULFATE EQ 0.09MG BASE/INH · POWDER, METERED, INHALATION · Discontinued

Clinical trials

Interventional ClinicalTrials.gov studies with "Albuterol" as an intervention, any sponsor and status, largest first.

All 793 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • dyspnoea13,701
  • wrong technique in product usage process11,012
  • no adverse event8,682
  • device delivery system issue8,121
  • drug dose omission by device7,917
  • asthma7,162
  • cough6,754
  • drug ineffective6,733
  • fatigue5,387
  • product dose omission issue5,192
  • headache5,109
  • off label use4,989

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004280
200592
200673
200799
2008345
2009162
2010191
2011353
2012496
2013540
2014665
20151,285
20162,554
20172,172
20182,274
20192,978
20206,335
20218,280
20229,922
202312,958
202415,218
202515,160
202611,094

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Proair Digihaler (Albuterol Sulfate)

2024 spending

$406K

Beneficiaries

3,126

3,914 claims

Per beneficiary

$130

$90.48 per unit

View as table
YearSpending
2020$99,879
2021$282,466
2022$520,797
2023$822,845
2024$405,518

Part D: Proair Respiclick (Albuterol Sulfate)

2024 spending

$4.5M

Beneficiaries

34,657

55,802 claims

Per beneficiary

$131

$65.66 per unit

View as table
YearSpending
2020$12,340,776
2021$8,258,921
2022$7,942,427
2023$11,858,276
2024$4,546,335

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 985 on PubMed

Sponsor: Teva · Also marketed as Proair Digihaler

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.